Patel Reema, Korenman Stanley, Weimer Amy, Grock Shira
Endocrinology, Diabetes and Metabolism, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, USA.
Endocrinology, Diabetes and Metabolism, University of California Los Angeles David Geffen School of Medicine, Los Angeles, USA.
Cureus. 2024 Jun 12;16(6):e62262. doi: 10.7759/cureus.62262. eCollection 2024 Jun.
Gender-affirming hormone therapy for assigned male at birth (AMAB) individuals with gender incongruence typically consists of estradiol with or without an anti-androgen to achieve physical changes and psychological benefits. However, prescribed hormone regimens vary considerably, and high-quality research in this area is extremely limited. Additional evidence-based research evaluating patient-reported outcome measures (PROMs) is needed to fill current knowledge gaps and create a personalized therapeutic approach for AMAB individuals. This editorial provides a critical description of current treatment options, discusses their variability, reviews some discrepancies in guideline-based dosing recommendations, and recommends areas for further study.
对于出生时被指定为男性（AMAB）且有性别不一致的个体，性别肯定激素疗法通常包括使用雌二醇，可加用或不加用抗雄激素，以实现身体变化和心理益处。然而，规定的激素治疗方案差异很大，该领域的高质量研究极其有限。需要更多基于证据的研究来评估患者报告的结局指标（PROMs），以填补当前的知识空白，并为AMAB个体创建个性化的治疗方法。这篇社论对当前的治疗选择进行了批判性描述，讨论了它们的变异性，回顾了基于指南的给药建议中的一些差异，并推荐了进一步研究的领域。
